-
Lung Cancer New Generation Target Drug Laura Tini: Significantly Improves the Progressless Lifetime of ALK-Positive Lung Cancer.
Time of Update: 2020-08-24
Pfizer announced positive results from the mid-term efficacy analysis of CROWN in Phase III clinical studies, and Larlatinib achieved a significant improvement in patients with progression-free survival (PFS) in patients with late-stage degenerative lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) compared to crizotinib.
-
What's the difference between 15 and 25 postoperative radiotherapy for breast cancer?
Time of Update: 2020-08-24
, the efficacy of breast cancer large division radiotherapy is comparable to conventional split radiotherapy, the treatment cycle is shorter, providing convenience for patients, but also to reduce the trend of acute side reactions.
-
Treatment or new progression of advanced neuroendocrine tumors! Hutchison Whampoa has submitted a marketing authorization application forUrufatinib to the EMA.
Time of Update: 2020-08-24
Hutchison Whampoa plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2021.
, China's National Drug Administration (NMPA) began reviewing Surufatinib's NDA for the treatment of patients with advanced non-pancreatic NET in November 2019.
-
Male, cough cough sputum 2 weeks chest tightness 1 week, please diagnose!
Time of Update: 2020-08-24
narrow bronchon - mainly manifested as smooth or irregular inner edge of the tube cavity, thickening of the pipe wall.
4. The tumor in the bronchal tube of central lung cancer needs to be distinguished from the benign nosedles of the bronchosis.
-
Blood:JAK/STAT inhibition enhances the sensitivity of CD8 T cells to desermison-induced apoptosis.
Time of Update: 2020-08-24
recently, researchers found that cytokine-induced JAK/STAT signals mediated the resistance of T-cell acute lymphoblastic leukemia (T-ALL) cells to d'isemison, which RUX can effectively reverse.
-
The lumbar vertebrae were "lighted" by the tumor an incision to remove the entire lumbar vertebral tumor and put the vertebral weight.
Time of Update: 2020-08-24
Aunt Wu, 66, was "lighted" by the tumor and stood magically after a doctor's hand replaced a vertebrae. days ago, Professor Fan Tao, director of the Spinal Spinal Surgery Center of Sanbo Brain Hospit
-
Roche Tecentriq did not reach the main endpoint of triple negative breast cancer research.
Time of Update: 2020-08-23
Roche announced today that Phase III Clinical Trials (IMpassion 131) of the anti-PD-L1 antibody Tecentriq (atezolizumab) in association with yew alcohol to treat metastatic triple negative breast cancer (TNBC) have failed to significantly improve progression-free survival (PFS).
-
Domestic innovative drugs ushered in a bright moment! CAR-T therapy is proposed to be included in the list of breakthrough therapeutic drugs.
Time of Update: 2020-08-23
new policies introduced by the State Drug Administration, including the implementation of breakthrough therapy, will strongly promote the further development of China's innovative pharmaceutical companies, according to Ding Jinxi, who is once again being courted by hot money.
-
PD-1 monoantivo combined with beret meth and chemotherapy: significantly improved progression-free survival in patients with non-small cell lung cancer.
Time of Update: 2020-08-23
Image source: Picture Source: In the ONO-4538-52/TASUKI-52 study, the Opdivo combination group (n s 275) was compared with a simple placebo combined with beva monotherapy and chemotherapy (placebo group: n s 275) in patients with IIIB/IV stage or recurrent non-squamous non-small cell lung cancer who were not suitable for radiotherapy.
-
Eur J Cancer: Follow-up results for 10 years of postoperative radiotherapy for early breast cancer.
Time of Update: 2020-08-23
results, after 9.89 years of mid-follow-up, 1 and 2 groups observed 10 cases and 31 cases of localized breast recurrence (IBRs), corresponding to 97.5% and 92.4% (p -0.004) respectively.
WBI and tumor grading were independent predictive factors without local recurrence.
-
Targeted TROP2 treatment drug DS-1062 is a rising star of NSCLC and breast cancer?
Time of Update: 2020-08-23
2019 ASCO reported the results of Phase I clinical trials of DS-1062 for the treatment of drug-resistant non-small cell lung cancer, which showed an objective remission rate of DS-1062a of more than 40%, a disease control rate of 80%, and more tolerable adverse reactions.
-
Ann Oncol: The tissue pathological characteristics of pCR patients after the new complementary treatment of melanoma are associated with the occurrence of no recurrence.
Time of Update: 2020-08-23
To determine whether the histopathological characteristics of pathological responses can be used to assess relapse risk, the study reviewed and analyzed surgical excision specimens from patients with new complementary treatments in phase II clinical trials and evaluated the relationship between tissue pathological characteristics such as active tumors, necrosis, melanin composure, and relative number of fibrosis (transparency or immaturity/progenitority) and patient prognosis.
-
Acta Neuropathologica: On-screen tube tumor CDKN2A deficiency with RELA change prompts poor prognosis: retrospective analysis of the HIT chamber tube membrane tumor test queue.
Time of Update: 2020-08-23
fusion between C11orf95 and RELA activates pathologically the NF-B signaling path caused by the nuclear build-up of p65-RelA.
all cases showed p65-RelA pathological nuclear build-up, which is the marker of RELA-EP.
-
Lancet oncol: Debio 1143 treats localized advanced head and neck squamous cell carcinoma.
Time of Update: 2020-08-23
study was conducted to study the efficacy and safety of Debio 1143 combined standard radiation chemotherapy in patients with high-risk local advanced head and neck squamous cell carcinoma.
-
Eur J Surg Oncol: Early evaluation of magnetic resonance imaging predicts the pathological response of triple negative breast cancer to new complementary chemotherapy.
Time of Update: 2020-08-23
study was conducted to determine the correlation between breast MRI results after the initial treatment of phase III BrighTNess and pCR in patients with triple negative breast cancer (TNBC).
, in the BrighTNess trial, a complete remission of the medium-term MRI showed a PCR PPV of 78% after TNBC completed NST.
-
1 case of spinal cytoblast osteosarcoma.
Time of Update: 2020-08-23
The literature reports that the typical GCRO is good in young people's feline backbone and tibia backbone end, the main image is shown as bone-soluble bone damage, bone damage area edge blurred, usually do not form soft tissue lumps, bone membrane reaction is not obvious.
-
2020 WCLC: Stage III data on the first-line treatment of non-squamous non-small cell lung cancer in combination with chemotherapy by Dabsch? (Sinead-Li mono-injection) is encouraging.
Time of Update: 2020-08-23
On August 8, 2020, Lilly Pharma (NYSE: LLY) and Syntech Biopharmaceuticals jointly announced that the results of the 21st World Lung Cancer Congress (IASLC WCLC) Online Theme Forum (IASLC WCLC) 2020 w
-
Cell: Relationship between tumor micro-environmental tissue distribution characteristics and tumor immune response?
Time of Update: 2020-08-23
authors suggest that comparing iTME in patients with CLR and DII using tissue imaging techniques may lead to the discovery of new iTME structures other than TLS to explore the relationship between cell arrangement structures and anti-tumor immune responses.
-
Am J Clin Oncol: The therapeutic effect of new assisted chemotherapy in patients with removable and marginal removable pancreatic cancer.
Time of Update: 2020-08-23
this study aims to report on our organization's experience with new complementary chemical radiotherapy (CRT) programmes in excision and edge removable pancreatic cancer.
the results showed that the new complementary treatment of CRT for marginally excisable and excisable pancreatic catheter adenocarcinoma promoted R0 excision in 84% of patients undergoing surgery.
-
Pyridine has been fully approved, and HER2 plus breast cancer treatment has entered a new era.
Time of Update: 2020-08-23
summary of the ASCO2019 conference, the results of the PHENIX study, Phase III data for the second-line treatment of Her2 plus breast cancer patients, were published.
